Thank you Daniel Chancellor for highlighting Evaluate's Orphan Drugs webinar later this month. Quick appetiser: by the end of the decade, Novo and Lilly's incretin twins - Ozempic/Wegovy and Mounjaro/Zepbound - may together sell a third as much as the ENTIRE orphan drug category. And they're only the first generation of (effective) skinny drugs. Just saying.
💡 Orphan Drugs - Are They Losing Their Sparkle: May 29, 3pm BST/10am ET
Puru Gaur will give the lowdown from Evaluate Ltd's latest orphan drug deep dive, with Melanie Senior and Stephanie Leouzon debating the implications of an apparent slow down in sales growth. Does this indicate a drop in investor and pharma appetite for rare diseases, or is it just a case of maturity. And how do new technologies and legislation affect the balance? Join us to find out.
https://lnkd.in/e_he3TQu